The use of generative artificial intelligence (AI) in clinical trial recruitment is rapidly changing how participants are identified, engaged, and enrolled. While the technology promises efficiency and broader reach, it also raises urgent ethical concerns. First, algorithmic bias in recruitment systems may reproduce or deepen health disparities, threatening efforts to build representative and inclusive clinical studies. Second, reliance on AI-generated patient materials complicates informed consent and transparency, since tailored outputs can obscure critical risks, oversimplify complex medical information, or frame participation in ways that undermine trust. Third, the integration of AI into recruitment workflows necessitates enhanced frameworks for accountability and responsible governance. Unlike traditional recruitment processes, generative AI involves layers of opacity, raising difficult questions about responsibility for errors, bias, and participant harm. Without strong regulatory oversight, the rapid adoption of AI-driven tools risks undermining participant protections and public trust in clinical research.
 
Kalina Kamenova PhD is Founder and Research Director of Canadian Institute For Genomics And Society | Toronto. Her work integrates bioethics, science policy, and public engagement strategies to shape evidence-based decisions in health and biomedical innovation, including genomics, precision medicine, stem cell and regenerative therapies, and artificial intelligence (AI) in healthcare. As Founder and Research Director of the Canadian Institute for Genomics and Society (Genomics4S), I have advanced participatory research, ethical governance, and policy innovation in emerging biotechnologies. Partnering with leading researchers, scientists, policymakers, and industry stakeholders, I have enabled strategic collaboration on initiatives that navigate the ethical and societal dimensions of biomedical innovation. With prior leadership experience at Loyalist College’s Applied Research and Innovation Office and University of Alberta’s Centre for Public Involvement, I have also contributed to fostering cross-sectoral innovation through applied research, policy development, and strategic partnerships. My executive and management expertise spans research administration, grant development, research ethics, team-building, and stakeholder engagement. I am driven by a commitment to responsible research and innovation, ensuring inclusive public discourse around transformative scientific advancements.

Other Posts

A recent article from The Atlantic talks about a Dutch psychiatrist who administered euthanasia to psychiatric patients including teenagers. These cases raise a difficult tension between autonomy versus vulnerability and choice versus illness. In the Netherlands, [...]

Japan has approved the world’s first treatments made from reprogrammed human cells, capable of becoming almost any tissue. These therapies aim to restore brain cells in Parkinson’s disease and repair damaged heart muscle. What makes [...]

During the 2025 Winter School, we had the honor of welcoming Dr. James Giordano as a guest speaker. He delivered a lecture on the convergence of neuroscience and artificial intelligence—an increasingly significant topic in today’s [...]

Chile has eliminated leprosy, becoming the first country in the Americas to reach this public health milestone. Leprosy, also known as Hansen’s disease, is a neglected tropical disease that affects the skin and nerves. The [...]

Scientists are developing synthetic womb technology that could support extremely premature infants outside the human body. The innovation has the potential to improve survival rates and reduce complications associated with premature birth by allowing continued [...]

Denmark has become the first country in the European Union to eliminate mother-to-child transmission of HIV and syphilis, marking an important milestone in maternal and public health. The achievement reflects decades of strong prenatal care [...]